First digital endpoint released by EMA (European Medicine Agency) for clinical studies (Actimyo)
SYSNAV’s disruptive Magneto-Inertial Technology offers an unparalleled solution: it enables precise measurement of patient movements and reconstructs their trajectory for analysis.
Our devices are made up of numerous inertial sensors which continuously collect precise 3-dimensional data. The data is transmitted remotely to our servers and is analyzed by our algorithms to reconstruct movement trajectories as well as whole acts. Our data scientists then use this data to identify relevant endpoints, allowing clinicians to analyze, compare and diagnose patient outcomes.
In 2019, SYSNAV HealthCare became the first global player to develop an endpoint recognised by the European Medicines Agency (EMA) as representative of the patient’s quality of life and suitable for use in clinical studies.
To know more about our projects :